Hospital
Mount Auburn Hospital
Mount Auburn Hospital was paid $27.96M by Medicaid between Jan 2018 and Dec 2024, across 307 billing codes. Its largest line is 99285, emergency room visit (most serious) — 14% of everything it billed.
33Billing provider infoMOUNT AUBURN HOSPITAL
CAMBRIDGE, MA 02138
CAMBRIDGE, MA 02138
33aNPI1689670259assigned 06/28/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.96M
24GClaims1,350,388
24DCodes billed307
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#35 of 66
Median peer was paid$29.11M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SMITH, BRIAN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 203,388 | $4.37M | |
| 2019 | 204,177 | $3.56M | |
| 2020 | 154,136 | $2.92M | |
| 2021 | 214,004 | $4.08M | |
| 2022 | 207,077 | $5.09M | |
| 2023 | 207,328 | $4.40M | |
| 2024incomplete | 160,278 | $3.55M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 25,634 | 21,266 | $3.87M |
| G0378 | Hospital observation service, per hour | 10.0% | 21,174 | 12,422 | $2.79M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.3% | 5,676 | 4,789 | $1.77M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.4% | 9,676 | 8,731 | $1.24M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.6% | 7,793 | 7,154 | $998K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.8% | 12,200 | 11,141 | $790K |
| S5161 | Emergency response system; service fee, per month (excludes installation and testing) | 2.6% | 43,894 | 42,496 | $736K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 2.5% | 4,533 | 4,084 | $693K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 9,285 | 3,855 | $483K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.7% | 22,162 | 21,149 | $476K |
| 76801 | 1.7% | 3,346 | 2,909 | $467K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.7% | 21,931 | 20,919 | $467K |
295 more codes
| 77063 | Screening digital breast tomosynthesis, bilateral | 1.6% | 6,527 | $445K |
| 59025 | Fetal non-stress test | 1.5% | 1,708 | $413K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.5% | 3,827 | $412K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.4% | 4,303 | $405K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 4,502 | $376K |
| 76819 | Fetal biophysical profile; without non-stress testing | 1.3% | 4,559 | $374K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 3,198 | $350K |
| 99219 | 1.3% | 2,645 | $350K | |
| 76830 | Ultrasound, transvaginal | 1.2% | 3,694 | $341K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.2% | 3,138 | $323K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.0% | 2,336 | $292K |
| 86481 | <1% | 5,014 | $268K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 7,282 | $264K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 63,616 | $253K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 29,379 | $253K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,497 | $251K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,767 | $248K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,491 | $240K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,974 | $228K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,394 | $227K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 14,908 | $209K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 12,114 | $209K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 7,239 | $202K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,180 | $198K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,503 | $196K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 41,214 | $189K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,110 | $173K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,845 | $165K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 10,348 | $157K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,815 | $153K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 191 | $149K |
| 76642 | <1% | 1,567 | $145K | |
| 86803 | <1% | 14,732 | $131K | |
| 80053 | Comprehensive metabolic panel | <1% | 41,900 | $127K |
| 80050 | General health panel | <1% | 11,803 | $126K |
| 87800 | <1% | 4,112 | $112K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 170 | $100K |
| 85027 | <1% | 27,043 | $100K | |
| 76813 | <1% | 1,138 | $99K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,857 | $99K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 969 | $97K |
| 93971 | <1% | 689 | $97K | |
| 82728 | <1% | 11,990 | $91K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,275 | $90K |
| 82607 | <1% | 11,989 | $89K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 42,860 | $88K |
| S9485 | Crisis intervention mental health services, per diem | <1% | 122 | $82K |
| 80061 | Lipid panel | <1% | 49,833 | $82K |
| ATP08 | <1% | 14,006 | $71K | |
| 87653 | <1% | 2,357 | $67K | |
| 73630 | <1% | 2,255 | $67K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 83 | $66K |
| 87340 | <1% | 9,555 | $64K | |
| 71250 | <1% | 1,015 | $60K | |
| 73562 | <1% | 1,714 | $60K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 241 | $58K |
| 83550 | <1% | 12,220 | $58K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 905 | $57K |
| 83655 | <1% | 5,315 | $56K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,034 | $54K |
| 86780 | <1% | 5,880 | $53K | |
| 84484 | <1% | 9,482 | $52K | |
| 86762 | <1% | 6,258 | $52K | |
| 84439 | <1% | 11,092 | $51K | |
| 86850 | <1% | 6,877 | $51K | |
| 84702 | <1% | 4,123 | $46K | |
| 81001 | <1% | 26,145 | $46K | |
| 83540 | <1% | 12,265 | $42K | |
| ATP15 | <1% | 6,099 | $40K | |
| 93017 | <1% | 619 | $39K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 857 | $38K |
| 84703 | <1% | 7,523 | $37K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,009 | $36K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,256 | $36K |
| 83690 | <1% | 9,072 | $36K | |
| 82248 | <1% | 31,977 | $36K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,150 | $36K |
| 87808 | <1% | 4,097 | $35K | |
| 86787 | <1% | 4,982 | $34K | |
| 86706 | <1% | 6,689 | $33K | |
| ATP14 | <1% | 4,355 | $33K | |
| 87070 | <1% | 4,998 | $30K | |
| 0002A | <1% | 1,006 | $30K | |
| 82746 | <1% | 4,140 | $29K | |
| 73610 | <1% | 1,168 | $29K | |
| 83970 | <1% | 1,786 | $29K | |
| 73030 | <1% | 1,236 | $28K | |
| 72100 | <1% | 856 | $27K | |
| 76536 | <1% | 287 | $27K | |
| 93976 | <1% | 453 | $26K | |
| 87102 | <1% | 4,355 | $26K | |
| 0001A | <1% | 1,110 | $26K | |
| 87186 | <1% | 5,014 | $26K | |
| 87205 | <1% | 4,795 | $26K | |
| 97161 | <1% | 693 | $25K | |
| 73502 | <1% | 1,166 | $24K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 552 | $23K |
| ATP18 | <1% | 4,582 | $23K | |
| 82043 | <1% | 10,233 | $23K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,077 | $23K |
| ATP03 | <1% | 5,098 | $23K | |
| 86900 | <1% | 7,422 | $22K | |
| 86140 | <1% | 7,752 | $22K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,147 | $22K |
| 86592 | <1% | 6,343 | $22K | |
| 77065 | Tomosynthesis, mammo | <1% | 516 | $22K |
| 83735 | <1% | 7,181 | $21K | |
| 87338 | <1% | 2,162 | $21K | |
| ATP11 | <1% | 3,853 | $20K | |
| 88342 | <1% | 961 | $20K | |
| 86901 | <1% | 7,421 | $19K | |
| 87081 | <1% | 3,453 | $19K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,372 | $18K |
| 77080 | <1% | 501 | $18K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 203 | $18K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,229 | $17K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 200 | $17K |
| 83880 | <1% | 1,688 | $16K | |
| 0011A | <1% | 614 | $16K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 629 | $16K |
| 87449 | <1% | 1,509 | $16K | |
| ATP17 | <1% | 2,163 | $16K | |
| 84403 | <1% | 1,096 | $16K | |
| 86735 | <1% | 3,350 | $15K | |
| 86765 | <1% | 3,377 | $14K | |
| 80076 | <1% | 7,344 | $14K | |
| 87077 | <1% | 3,178 | $14K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,676 | $14K |
| 0012A | <1% | 518 | $14K | |
| 86704 | <1% | 2,685 | $13K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 61 | $12K |
| 82570 | <1% | 5,004 | $12K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 337 | $12K |
| 81025 | <1% | 2,271 | $11K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,879 | $11K |
| 73130 | <1% | 331 | $10K | |
| 85652 | <1% | 7,134 | $10K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,516 | $10K |
| 84153 | <1% | 1,360 | $10K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 2,762 | $10K |
| ATP04 | <1% | 2,392 | $10K | |
| 85610 | <1% | 5,938 | $10K | |
| 86708 | <1% | 2,060 | $10K | |
| 82950 | <1% | 2,254 | $9K | |
| 83605 | <1% | 1,795 | $9K | |
| 83021 | <1% | 600 | $9K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,266 | $9K |
| ATP07 | <1% | 1,640 | $9K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,042 | $9K |
| 84480 | <1% | 1,426 | $8K | |
| 86480 | <1% | 162 | $8K | |
| 83721 | <1% | 2,246 | $8K | |
| 83001 | <1% | 845 | $8K | |
| 97162 | <1% | 311 | $7K | |
| 87147 | <1% | 1,254 | $7K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,429 | $7K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 551 | $7K |
| 87106 | <1% | 985 | $7K | |
| 85018 | <1% | 3,625 | $7K | |
| 71271 | <1% | 188 | $7K | |
| 81003 | <1% | 4,959 | $6K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,365 | $6K |
| 84146 | <1% | 727 | $6K | |
| 85378 | <1% | 1,347 | $6K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 77 | $6K |
| 76770 | <1% | 57 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 57,419 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,353 | $5K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 57 | $5K |
| ATP10 | <1% | 1,003 | $5K | |
| 85007 | <1% | 2,773 | $5K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 75 | $5K |
| 86682 | <1% | 1,272 | $5K | |
| 86038 | <1% | 723 | $5K | |
| 84402 | <1% | 351 | $5K | |
| 85014 | <1% | 2,740 | $5K | |
| 77336 | <1% | 55 | $5K | |
| 84460 | <1% | 6,354 | $4K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 429 | $4K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,780 | $4K |
| 97803 | <1% | 65 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,350 | $3K |
| 82565 | <1% | 3,979 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 96 | $3K |
| ATP09 | <1% | 790 | $3K | |
| 83615 | <1% | 4,882 | $3K | |
| 77062 | <1% | 37 | $3K | |
| 82784 | <1% | 422 | $3K | |
| 99205 | Prolong outpt/office vis | <1% | 15 | $3K |
| 88341 | <1% | 124 | $3K | |
| 73110 | <1% | 132 | $3K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 131 | $2K |
| 85730 | <1% | 956 | $2K | |
| 90715 | <1% | 95 | $2K | |
| 84450 | <1% | 4,476 | $2K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 20 | $2K |
| 86618 | <1% | 245 | $2K | |
| 81514 | <1% | 411 | $2K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 4,068 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 206 | $2K |
| 86141 | <1% | 298 | $2K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 19 | $2K |
| 84100 | <1% | 2,957 | $2K | |
| 84156 | <1% | 764 | $2K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 356 | $1K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 54 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,336 | $1K |
| 87522 | Neg quan hep c or qual rna | <1% | 80 | $1K |
| 84550 | <1% | 3,415 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,078 | $1K |
| 84165 | <1% | 334 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 230 | $1K |
| 77061 | <1% | 13 | $1K | |
| 90686 | <1% | 97 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 401 | $1K |
| 82550 | <1% | 1,035 | $1K | |
| ATP12 | <1% | 300 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,137 | $1K |
| C7901 | Service for diagnosis, evaluation, or treatment of a mental health or substance use disorder, 30-60 minutes, provided remotely by hospital staff who are licensed to provided mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service | <1% | 1,017 | $1K |
| 86255 | <1% | 167 | $1K | |
| 87040 | <1% | 195 | $1K | |
| ATP16 | <1% | 231 | $1K | |
| 86431 | <1% | 461 | $995.16 | |
| 83002 | <1% | 116 | $982.89 | |
| 74018 | <1% | 44 | $947.91 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 149 | $829.44 |
| 82670 | <1% | 66 | $813.12 | |
| 84520 | <1% | 3,151 | $789.64 | |
| ATP13 | <1% | 103 | $784.08 | |
| 88304 | <1% | 104 | $781.26 | |
| 82040 | <1% | 2,234 | $771.15 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 35 | $658.56 |
| 84425 | <1% | 38 | $654.94 | |
| 82951 | <1% | 55 | $640.63 | |
| 82947 | <1% | 307 | $607.40 | |
| 87536 | <1% | 19 | $525.42 | |
| S5160 | Emergency response system; installation and testing | <1% | 16 | $516.31 |
| ATP02 | <1% | 248 | $494.04 | |
| 82962 | <1% | 6,239 | $490.11 | |
| 82803 | <1% | 44 | $391.44 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,192 | $385.79 |
| 83883 | <1% | 42 | $355.74 | |
| 86769 | <1% | 13 | $337.04 | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 16 | $314.97 |
| 86753 | <1% | 44 | $284.18 | |
| 86376 | <1% | 28 | $269.43 | |
| 82150 | <1% | 76 | $263.62 | |
| 82652 | <1% | 12 | $237.72 | |
| 87046 | <1% | 59 | $234.20 | |
| 86200 | <1% | 26 | $232.30 | |
| 85045 | <1% | 191 | $228.04 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 485 | $221.74 |
| 87045 | <1% | 59 | $215.84 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 16 | $215.20 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 43 | $160.78 |
| 82533 | <1% | 12 | $158.18 | |
| 82627 | <1% | 13 | $156.88 | |
| 87177 | <1% | 21 | $129.92 | |
| 87427 | <1% | 48 | $122.95 | |
| 84481 | <1% | 13 | $122.29 | |
| 82247 | <1% | 60 | $115.39 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 114 | $115.36 |
| 73560 | <1% | 18 | $111.64 | |
| G0008 | Administration of influenza virus vaccine | <1% | 71 | $111.40 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 108 | $80.39 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 609 | $79.42 |
| 84155 | <1% | 1,743 | $75.18 | |
| 87075 | <1% | 19 | $66.80 | |
| 82465 | <1% | 101 | $58.24 | |
| ATP05 | <1% | 12 | $57.19 | |
| 96376 | <1% | 1,804 | $43.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,074 | $25.00 |
| 84075 | <1% | 12 | $18.39 | |
| 85048 | <1% | 12 | $7.83 | |
| 80178 | <1% | 13 | $6.82 | |
| 84132 | <1% | 17 | $4.20 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 5,909 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 162 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 128 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 27 | $0.00 |
| 91300 | 0% | 968 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 14 | $0.00 |
| 99222 | Initial hospital care, per day, moderate complexity | 0% | 15 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 72 | $0.00 |
| 76376 | 0% | 14 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 12 | $0.00 |
| 36591 | 0% | 85 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 407 | $0.00 |
| 91301 | 0% | 551 | $0.00 | |
| 36416 | 0% | 108 | $0.00 | |
| C1769 | Guide wire | 0% | 26 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 83 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 231 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 14 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, BRIAN (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.